Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review

• Κύριοι συγγραφείς: Lumin Wang (Συγγραφέας), Qining Qiu (Συγγραφέας), Dawei Yang (Συγγραφέας), Chang Cao (Συγγραφέας), Yanqin Lu (Συγγραφέας), Yulan Zeng (Συγγραφέας), Weiwen Jiang (Συγγραφέας), Yun Shen (Συγγραφέας), Yanrong Ye (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Rapamycin, an established mTOR inhibitor in clinical practice, is widely recognized for its therapeutic efficacy. Ridaforolimus, a non-prodrug rapalog, offers improved aqueous solubility, stability, and affinity compared to rapamycin. In recent years, there has been a surge in clinical trials involv...